Angela Emperatriz Centeno-Lopez

Angela Emperatriz Centeno-Lopez

Auto-generated profile, based on publicly available information

Angela Emperatriz Centeno-Lopez

Computational Biology and Chemistry Research Group, Vicerrectorado de Investigación, Universidad Catolica de Santa Maria de Arequipa, Pedro Vilcapaza, Arequipa, 04000

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Haruna L. Barazorda-CcahuanaHaruna L. Barazorda-Ccahuana
Haruna L. Barazorda-Ccahuana
ECEymi Gladys Cárcamo-Rodriguez
Eymi Gladys Cárcamo-Rodriguez
ACAngela Emperatriz Centeno-Lopez
Angela Emperatriz Centeno-Lopez
ALEXSANDRO SOBREIRA GALDINOALEXSANDRO SOBREIRA GALDINO
ALEXSANDRO SOBREIRA GALDINO
RMRicardo Andrez Machado-de-Ávila
Ricardo Andrez Machado-de-Ávila
Miguel Angel Chavez FumagalliMiguel Angel Chavez Fumagalli
Miguel Angel Chavez Fumagalli
Visceral Leishmaniasis (VL) has a high death rate, with 500,000 new cases and 50,000 deaths occurring annually. Despite the development of novel strategies and technologies, there is no adequate treatment for the disease. Therefore, the purpose of this study is to find structural analogs of natural products as potential novel drugs to treat VL. We selected structural analogs from natural products that have shown antileishmanial activities, and that may impede the purine salvage pathway using computer-aided drug-design (CADD) approaches. For these, we started with the vastly studied target in the pathway, the adenine phosphoribosyl transferase (APRT) protein, which alone is non-essential for the survival of the parasite. Keeping this in mind, we search for a substance that can bind to multiple targets throughout the pathway. Computational techniques were used to study the purine salvage pathway from Leishmania infantum, and molecular dynamic simulations were used to gather information on the interactions between ligands and proteins. Because of its low homology to human proteins and its essential role in the purine salvage pathway proteins network interaction, the findings further highlight the significance of adenylosuccinate lyase protein (ADL) as a therapeutic target. An analog of the alkaloid Skimmianine, N,N-diethyl-4-methoxy-1-benzofuran-6-carboxamide, demonstrated a good binding affinity to APRT and ADL targets, no expected toxicity, and potential for oral route administration. This study indicates that the compound may have antileishmanial activity, which was granted in vitro and in vivo experiments to settle this finding in the future.

18 January 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
Haruna L. Barazorda-CcahuanaHaruna L. Barazorda-Ccahuana
Haruna L. Barazorda-Ccahuana
Lena Gálvez RanillaLena Gálvez Ranilla
Lena Gálvez Ranilla
Mayron Antonio Candia PumaMayron Antonio Candia Puma
Mayron Antonio Candia Puma
ECEymi Gladys Cárcamo-Rodriguez
Eymi Gladys Cárcamo-Rodriguez
ACAngela Emperatriz Centeno-Lopez
Angela Emperatriz Centeno-Lopez
Miguel Angel Chavez FumagalliMiguel Angel Chavez Fumagalli
Miguel Angel Chavez Fumagalli
Since the number of drugs based on natural products (NPs) represents a large source of novel pharmacological entities, NPs have acquired significance in drug discovery. Peru is considered a megadiverse country with many endemic species of plants, terrestrial, and marine animals, and microorganisms. NPs databases have a major impact on drug discovery development. For this reason, several countries such as Mexico, Brazil, India, and China have initiatives to assemble and maintain NPs databases that are representative of their diversity and ethnopharmacological usage. We describe the assembly, curation, and full chemoinformatic evaluation of the content and coverage in chemical space, as well as the physicochemical attributes and chemical diversity of the initial version of the Peruvian Natural Products Database (PeruNPDB), which contains 280 compounds. Access to PeruNPDB is available for free ( https://perunpdb.com.pe/ ). The PeruNPDB’s collection is intended to be used in a variety of tasks, such as virtual screening campaigns against various disease targets or biological endpoints. This emphasizes the significance of biodiversity protection both directly and indirectly on human health.

22 November 2024 in F1000Research
Verified
Journal Article
Open access
PDF file
Haruna L. Barazorda-CcahuanaHaruna L. Barazorda-Ccahuana
Haruna L. Barazorda-Ccahuana
EREymi Gladys Cárcamo Rodriguez
Eymi Gladys Cárcamo Rodriguez
ACAngela Emperatriz Centeno-Lopez
Angela Emperatriz Centeno-Lopez
MCMargot Paco Chipana
Margot Paco Chipana
Luis Daniel Goyzueta-MamaniLuis Daniel Goyzueta-Mamani
Luis Daniel Goyzueta-Mamani
Miguel Angel Chavez FumagalliMiguel Angel Chavez Fumagalli
Miguel Angel Chavez Fumagalli
Background Although the COVID-19 pandemic has diminished in intensity, the virus continues to circulate globally. The SARS-CoV-2 main protease (Mpro) is a key enzyme in the life cycle of the virus, making it important for the development of treatments against future variants of the virus. In this work, Peruvian natural compounds were evaluated against different mutations of the SARS-CoV-2 Mpro. Methods In silico techniques such as virtual screening, all-atom molecular dynamics simulations, and energy estimation analysis were applied. Results Of the tested compounds by virtual screening, rutin was identified as the best binding agent against the different proposed Mpro mutations. In addition, computational simulations and energy estimation analysis demonstrated the high structural and energetic stability between the Mpro-rutin systems. Conclusions Overall, our study identified rutin as the most promising compound with a strong affinity for various Mpro mutations, potentially playing a key role in the development of new treatments for emerging viral variants.

29 October 2024 in F1000Research
Verified
Journal Article
Open access
PDF file
Haruna L. Barazorda-CcahuanaHaruna L. Barazorda-Ccahuana
Haruna L. Barazorda-Ccahuana
EREymi Gladys Cárcamo Rodriguez
Eymi Gladys Cárcamo Rodriguez
ACAngela Emperatriz Centeno-Lopez
Angela Emperatriz Centeno-Lopez
MCMargot Paco Chipana
Margot Paco Chipana
Luis Daniel Goyzueta-MamaniLuis Daniel Goyzueta-Mamani
Luis Daniel Goyzueta-Mamani
Miguel Angel Chavez FumagalliMiguel Angel Chavez Fumagalli
Miguel Angel Chavez Fumagalli
Background Although the COVID-19 pandemic has diminished in intensity, the virus continues to circulate globally. The SARS-CoV-2 main protease (Mpro) is a key enzyme in the life cycle of the virus, making it important for the development of treatments against future variants of the virus. In this work, Peruvian natural compounds were evaluated against different mutations of the SARS-CoV-2 Mpro. Methods In silico techniques such as virtual screening, all-atom molecular dynamics simulations, and energy estimation analysis were applied. Results Of the tested compounds by virtual screening, rutin was identified as the best binding agent against the different proposed Mpro mutations. In addition, computational simulations and energy estimation analysis demonstrated the high structural and energetic stability between the Mpro-rutin systems. Conclusions Overall, our study identified rutin as the most promising compound with a strong affinity for various Mpro mutations, potentially playing a key role in the development of new treatments for emerging viral variants.

15 May 2023 in ChemRxiv
Verified
Preprint
Open access
PDF file
Haruna L. Barazorda-CcahuanaHaruna L. Barazorda-Ccahuana
Haruna L. Barazorda-Ccahuana
Luis Daniel Goyzueta-MamaniLuis Daniel Goyzueta-Mamani
Luis Daniel Goyzueta-Mamani
EREymi Gladys Cárcamo Rodriguez
Eymi Gladys Cárcamo Rodriguez
ALAngela Emperatriz Centeno Lopez
Angela Emperatriz Centeno Lopez
MCMargot Paco Chipana
Margot Paco Chipana
Miguel Angel Chavez FumagalliMiguel Angel Chavez Fumagalli
Miguel Angel Chavez Fumagalli
The COVID-19 pandemic continues to be a public health problem worldwide. Several therapeutic targets of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been identified, whereas the main protease (Mpro) is necessary for virus replication. Since SARS-CoV-2 Mpro mutation rates are inherently high, searching for new inhibitors remains challenging. Herein, this work aimed to evaluate eighty-four natural compounds from Peruvian sources against different mutations on the Mpro target. Using computational technics, we applied virtual screening, all-atom molecular dynamics simulations, and binding free energy estimation by MM/GBSA methods. The virtual screening results helped us identify rutin as the top compound against different Mpro mutations. Likewise, the computational simulations demonstrated the high structural stability of the Mpro-rutin system. Our results demonstrated the antiviral capacity of compounds from Peruvian sources against SARS-CoV-2 Mpro and its mutations, which could significantly prevent and treat SARS-CoV-2 infection.

29 November 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
Haruna L. Barazorda-CcahuanaHaruna L. Barazorda-Ccahuana
Haruna L. Barazorda-Ccahuana
ECEymi Gladys Cárcamo-Rodriguez
Eymi Gladys Cárcamo-Rodriguez
ACAngela Emperatriz Centeno-Lopez
Angela Emperatriz Centeno-Lopez
ALEXSANDRO SOBREIRA GALDINOALEXSANDRO SOBREIRA GALDINO
ALEXSANDRO SOBREIRA GALDINO
RMRicardo Andrez Machado-de-Ávila
Ricardo Andrez Machado-de-Ávila
Miguel Angel Chavez FumagalliMiguel Angel Chavez Fumagalli
Miguel Angel Chavez Fumagalli
Visceral Leishmaniasis (VL) has a high death rate with 500,000 new cases and 50,000 deaths occurring annually. Despite the development of novel strategies and technologies, there is no adequate treatment for the disease. Therefore, the purpose of this study is to find structural analogs of natural products as potential novel drugs to treat VL. To choose structural analogs from natural products that have demonstrated anti-leishmanial and anti-adenine phosphoribosyltransferase (APRT) properties, and that might bind with several targets from the purine salvage pathway, we used computer-aided drug design (CADD) techniques. Computational techniques were used to study the purine salvage pathway from Leishmania infantum , and molecular dynamic simulations were used to gather information on the interactions between ligands and proteins. An analog of the alkaloid Skimmianine, N,N-diethyl-4-methoxy-1-benzofuran-6-carboxamide, demonstrated a good binding affinity to two L. infantum targets, no expected toxicity, and potential for oral route administration. This study indicates that the compounds may have anti-leishmanial activity, which granted in vitro and in vivo experiments to settle this finding in the future.